International Goals

Within the United Nations Sustainable Development Goal 3, the target 3.3 is: End TB by 2030.

MPP’s Contribution

Licensing new treatments and contributing to their sustainable use in developing countries with the highest TB burden.

Tuberculosis (TB) is a global pandemic affecting 10.4 million people worldwide. In 2015, TB caused 1.8 million deaths, and it is among the leading causes of death for people living with HIV. More than 95% of TB deaths occur in low- and middle-income countries.[1]

The WHO’s post-2015 Global TB Strategy sets ambitious targets aimed at reducing TB deaths by 95% between 2015 and 2035, and to end TB. To meet these targets, faster acting, better therapies to treat TB are urgent, particularly for multidrug-resistant TB (MDR-TB).

We work to improve access to new treatments for MDR-TB and drug-susceptible tuberculosis. We also facilitate the development of new regimens by licensing TB drugs that are still under development. In early 2017, we signed our first licence for a TB treatment.

[1] World Health Organization, Global Tuberculosis Report 2016